|Dr. Joseph K. Belanoff||Co-Founder, Pres, CEO & Director||1.16M||3.44M||1957|
|Mr. Gary Charles Robb||CFO & Sec.||674.27k||378.25k||1963|
|Mr. Sean Maduck||Sr. VP of Commercial||634.67k||1.16M||1977|
|Dr. Christopher Shayne James M.D.||Director of Investor Relations||N/A||N/A||N/A|
|Dr. Hazel Hunt Ph.D.||Sr. VP of Research||N/A||N/A||N/A|
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant that is in Phase III clinical trial to treat patients with Cushing's syndrome; and Abraxane in combination with relacorilant, which is in Phase II clinical trial to treat metastatic ovarian cancer, as well as in Phase I/II clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator CORT125281 combined with Xtandi that is in open label Phase I/II trial to treat patients with metastatic castration-resistant prostate cancer; CORT118335 selective cortisol modulator for the treatment of antipsychotic-induced weight gain and non-alcoholic steatotic hepatitis; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Corcept Therapeutics Incorporated’s ISS Governance QualityScore as of October 4, 2019 is 6. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 6; Compensation: 7.